期刊
JOURNAL OF CARDIOLOGY
卷 76, 期 5, 页码 459-463出版社
ELSEVIER
DOI: 10.1016/j.jjcc.2020.03.013
关键词
Cardiomyocyte; Pluripotent stem cell; Heart disease; Transplantation; Cell therapy
资金
- Japan Society for the Promotion of Science [KAKENHI19K17554, 17H04173, 18K19539]
- Grants-in-Aid for Scientific Research [17H04173, 18K19539] Funding Source: KAKEN
Pluripotent stem cells (PSCs), which include embryonic and induced pluripotent stem cells (ESCs and iPSCs, respectively), have great potential in regenerative medicine for heart diseases due to their virtually unlimited cardiogenic capacity. Many preclinical studies have described the functional benefits after transplantation of PSC-derived cardiomyocytes (PSC-CMs). However, transient ventricular arrhythmias were detected after injection into non-human primates and swine ischemic hearts; as engrafted PSC-CMs form an electrical coupling between host and graft, the immature characteristics of PSC-CMs may serve as an ectopic pacemaker. We are entering a critical time in the development of novel therapies using PSC-CMs, with the recent first clinical trial using human iPSC-CMs (hiPSC-CMs) being launched in Japan. In this review, we summarize the updated knowledge, perspectives, and limitations of PSC-CMs for heart regeneration. (C) 2020 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据